Application

Research CategorySignaling

Anti-vaccinia related kinase-1, N-Terminus, Cat. No. ABS2113, is a rabbit polyclonal antibody that detects Serine/threonine-protein kinase VRK1 (vaccinia related kinase 1) and has been tested for use in ELISA, and Western Blotting.

Western Blotting Analysis: 1 µg/mL from a representative lot detected Vaccinia related kinase-1, N-Terminus in HT1080 cell lysate.

Western Blotting Analysis: 1:50 diluton from a representative lot detected vaccinia related kinase-1, N-Terminus in HeLa cell lysate (Courtesy of Dr. Ito Takashi at Nagasaki University).

Western Blotting Analysis: A representative lot detected Vaccinia related kinase-1, N-Terminus in HT1080 cell lysate (Aihara, H., et. al. (2016). Mol Cell. 64(1):176-188).

Enzyme Immunoassay Analysis: A representative lot detected Vaccinia related kinase-1, N-Terminus in ELISA application (Aihara, H., et. al. (2016). Mol Cell. 64(1):176-188).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Serine/threonine-protein kinase VRK1 (UniProt: Q99986; also known as EC: 2.7.11.1, Vaccinia-related kinase 1) is encoded by the VRK1 gene (Gene ID: 7443) in human. VRK1 is a serine/threonine kinase that is widely expressed with high expression in fetal liver, testis and thymus. Its protein kinase domain is located in the amino acids 37-317. VRK1 is involved in Golgi disassembly during the cell cycle and Golgi fragmentation. VRK1 phosphorylation by PLK3, which leads to induction of Golgi fragmentation. VRK1 acts by mediating phosphorylation of downstream target protein and is shown to phosphorylate threonine 18 of p53/TP53 and thereby prevent the interaction between p53/TP53 and MDM2. VRK1 is autophosphorylated at various serine and threonine residues, however, it does not impair its ability to phosphorylate p53/TP53. VRK1 is also shown to phosphorylate casein, histone H3, and ATF2, which activates its transcriptional activity. In cancer cell lines VRK1 is reported to phosphorylate histone H2A at threonine 120 that results in inappropriate gene expression, including up-regulation of cyclin D1, which can promote oncogenic transformations. Mutations in VRK1 gene have been linked to Pontocerebellar hypoplasia 1A, a condition characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth. (Ref.: Aihara, H., et al., (2016). Mol. Cell 64(1); 176-188).

Immunogen

KLH-conjugated linear peptide corresponding to 30 amino acids from the N-terminal region of human Vaccinia-related kinase 1 (VRK1).

Epitope: N-terminus

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified rabbit polyclonal antibody in buffer containing 50 mM KCl, 25 mM HEPES (pH 7.6), 10% glycerol, 0.1 mM EDTA, 0.01% NP40 with 0.05% sodium azide.

Affinity Purified

Format: Purified

Quality

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: 1 µg/mL of this antibody detected vaccinia related kinase 1, N-Terminus in HeLa cell lysate.

Specificity

This rabbit polyclonal antibody detects Serine/threonine-protein kinase VRK1 in human cells. It targets an epitope within 30 amino acids from the N-terminal region.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.

Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Target description

~ 47 kDa observed; 45.48 kDa calculated. Uncharacterized bands may be observed in some lysate(s).